Showing results (401-410 of 757) with videos related to
Sort By:
Pageof 76
Eclinicalmedicine|January 10, 2022
Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomesPiero Ruggenenti, Bettina J Kraus, Silvio E Inzucchi, et al.Biomolecules & Biomedicine|July 26, 2022
Risk of graft loss in kidney transplant recipients after aortic valve replacementStefan Büttner, Carolin Zöller, Sammy Patyna, et al.Clinical Journal of the American Society of Nephrology : CJASN|April 16, 2011
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysisWinfried März, Bernd Genser, Christiane Drechsler, et al.Diabetes Care|April 26, 2022
Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical TrialsKatherine R Tuttle, Adeera Levin, Masaomi Nangaku, et al.Kidney International|May 31, 2019
Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamicsGert J Mayer, Christoph Wanner, Matthew R Weir, et al.European Heart Journal|August 7, 2010
Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patientsChristiane Drechsler, Stefan Pilz, Barbara Obermayer-Pietsch, et al.European Heart Journal|January 29, 2016
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trialDavid Fitchett, Bernard Zinman, Christoph Wanner, et al.Circulation|September 15, 2017
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney DiseaseChristoph Wanner, John M Lachin, Silvio E Inzucchi, et al.Journal of the American Society of Nephrology : JASN|April 29, 2005
Prediction of acute renal allograft rejection by urinary monokine induced by IFN-gamma (MIG)Ingeborg A Hauser, Sandra Spiegler, Eva Kiss, et al.European Heart Journal|December 30, 2021
Kidney function assessment and endpoint ascertainment in clinical trialsMuhammad Shahzeb Khan, George L Bakris, Milton Packer, et al.Pageof 76